Biolux Technology funding news – Vienna-based Biolux Technology has Secured €4.26 Million in Funding

Utilisation of funding

Biolux will use the funds to launch a smart digital platform for its flagship product, OrthoPulse®, offering real-time monitoring and treatment optimization for both orthodontists and patients.

This will further OrthoPulse®’s mission to enhance orthodontic treatments through cutting-edge technology and research-driven innovations. In 2023, orthodontic market valued at USD 9 billion (12 million cases) and expected to grow at 15% CAGR to reach USD 21 billion by 2030 (30 million cases).

Read more : Prelude funding news – Paris-based Prelude has Raised €7.6 Million in Seed Funding

Alongside these developments, Biolux Technology also announced the appointment of Raphael Pascaud as Chairman of the Board. Mr. Pascaud brings a wealth of leadership experience from his roles on various boards and executive positions in the dental industry including at companies like DentalMonitoring and Align Technology. With his deep industry expertise Mr. Pascaud will help in steering Biolux through its next phase of growth and innovation.

Marcel Pordes, CEO of Biolux Technology, said: "We are thrilled to partner with both redalpine and Revere Partners, and welcome Raphael Pascaud as our Chairman. This investment, along with our new digital platform for OrthoPulse®, represents a critical milestone in our journey to revolutionize orthodontics. We are committed to providing patients with faster, more efficient treatment options, and ensuring orthodontists have the tools they need to deliver exceptional care."

Daniel Dillinger, Principal at redalpine, said: “Biolux is already transforming orthodontics and delivering exceptional patient outcomes with its FDA-cleared, patented, and commercially successful flagship product, OrthoPulse®. We’re delighted to partner with the Biolux team as they enter the next phase of growth, further enhancing the state-of-the-art user experience to support their rapid scaling and expansion in the U.S. market.”

OrthoPulse Future Generation Planning

The next-generation OrthoPulse® features an exclusive, patented light-accelerated technology and an exceptionally low failure rate for more reliable treatment. Using safe near-infrared light therapy, OrthoPulse® accelerates tooth movement, cutting treatment times by up to 50%.

This game-changing approach not only shortens the orthodontic process but also tackles a critical issue in patient care - longer treatments often lead to reduced compliance and more expensive, time-consuming refinements.

With this new funding, Biolux Technology will accelerate the development of OrthoPulse®, advance clinical research, and develop innovative solutions that improve patient outcomes and revolutionize orthodontic treatment worldwide.

About Biolux Technology

Biolux Technology is a leading innovator in light-accelerated orthodontics, dedicated to developing advanced technologies that improve patient outcomes and treatment experiences.

The company’s flagship product, OrthoPulse® uses near-infrared light therapy to safely and effectively accelerate tooth movement, reduce treatment time and treatment discomfort. Thus, OrthoPulse® improves the predictability of aligner treatments, enhancing the overall orthodontic experience.